Maxidex®
Dexamethasone 0.1% · ophthalmic suspension
Steroid
Approved uses
Steroid-responsive inflammation of the conjunctiva, cornea, and anterior segment
1 to 2 drops in the conjunctival sac; hourly in severe disease with taper as inflammation subsides, up to 4 to 6 times daily in mild disease; not more than one bottle before re-examination
Contraindications
- Acute, untreated bacterial infections
- Mycobacterial ocular infections
- Epithelial herpes simplex (dendritic keratitis)
- Vaccinia, varicella, and most other viral diseases of the cornea and conjunctiva
- Fungal disease of ocular structures
- Hypersensitivity to any component of this preparation
0.1% suspension, 5 mL plastic dropper bottle.
Corticosteroid; dexamethasone suppresses the inflammatory response to a variety of agents and it probably delays or slows healing.
Warnings & Precautions
- Ocular hypertension and/or glaucoma: Prolonged use may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation.
- Secondary ocular infections: Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. The possibility of persistent fungal infections of the cornea should be considered after prolonged corticosteroid dosing.
- Infection masking: In acute purulent conditions or parasitic infections of the eye, corticosteroids may mask infection or enhance existing infection.
- Perforation: In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical corticosteroids.
- IOP monitoring at 10 days: If used for 10 days or longer, intraocular pressure (IOP) should be routinely monitored even though it may be difficult in children and uncooperative patients.
- Herpes simplex: Contraindicated in epithelial (dendritic) keratitis; other forms of ocular herpes simplex require great caution and periodic slit lamp microscopy.
- Steroid IOP response: In a randomized fellow-eye trial in 20 children undergoing bilateral recession strabismus surgery, two weeks of dexamethasone 0.1% in one eye and rimexolone 1% in the fellow eye gave week 2 IOP of 17.95 mmHg versus 14.15 mmHg, and IOP returned to near preoperative values over the following four consecutive weeks. None of the patients were high responders.
- Examination before prescribing: The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.
- Two-day reassessment: Re-evaluate if signs and symptoms fail to improve after 2 days.
- Contamination: Do not touch dropper tip to any surface, as this may contaminate the contents.
- Soft contact lenses: Benzalkonium chloride 0.01% may be absorbed by soft lenses; do not instill while lenses are worn.
Common Side Effects
The most frequent adverse reactions in clinical studies were ocular discomfort (approximately 10%) and eye irritation (approximately 1%). Others occurred in less than 1%, including keratitis, conjunctivitis, dry eye, photophobia, blurred vision, eye pruritus, foreign body sensation, increased lacrimation, abnormal ocular sensation, eyelid margin crusting, and ocular hyperemia. Glaucoma with optic nerve damage, visual acuity and field defects, cataract formation, secondary ocular infection following suppression of host response, and perforation of the globe may occur. Postmarketing reactions include corneal erosion, dizziness, eye pain, eyelid ptosis, headache, hypersensitivity reactions, and mydriasis. Cushing's syndrome and adrenal suppression may occur after use in excess of the listed dosing in predisposed patients, including children and patients treated with CYP3A4 inhibitors.
Pregnancy: Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application in multiples of the therapeutic dose; in the mouse, corticosteroids produce fetal resorptions and cleft palate, and in the rabbit, fetal resorptions and multiple abnormalities involving the head, ears, limbs, palate, etc. Use during pregnancy only if the potential benefit to the mother justifies the potential risk to the embryo or fetus. There are no adequate or well-controlled studies in pregnant women, but prolonged or repeated corticoid use during pregnancy has been associated with an increased risk of intra-uterine growth retardation, and infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be observed carefully for signs of hypoadrenalism.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, use caution when MAXIDEX is given to a nursing woman.
Safety and effectiveness established in all pediatric age groups, supported by adult trials plus pediatric safety data.